MedTrace Logo

Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax

NCT00826852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2010-07-27

No results posted yet for this study

Summary

The purpose of this study is:

* to assess the efficacy of the combination in terms of Objective (clinical and radiological) Response Rate
* to assess the time to progression of the disease; assess the safety profile of the combination, and assess the survival time.

Conditions

  • Lung Neoplasms

Interventions

DRUG

docetaxel and carboplatin

weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5

Sponsors & Collaborators

Principal Investigators

  • Edibe Taylan, MD · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826852 on ClinicalTrials.gov